PL347719A1 - Multivalent t.d. polio vaccine against at least diphtheria, poliomyelitis and tetanus - Google Patents

Multivalent t.d. polio vaccine against at least diphtheria, poliomyelitis and tetanus

Info

Publication number
PL347719A1
PL347719A1 PL99347719A PL34771999A PL347719A1 PL 347719 A1 PL347719 A1 PL 347719A1 PL 99347719 A PL99347719 A PL 99347719A PL 34771999 A PL34771999 A PL 34771999A PL 347719 A1 PL347719 A1 PL 347719A1
Authority
PL
Poland
Prior art keywords
vaccine
diphtheria
poliomyelitis
tetanus
multivalent
Prior art date
Application number
PL99347719A
Other languages
English (en)
Inventor
Jean Rene Cartier
Patrick Laroche
Original Assignee
Aventis Pasteur Msd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8233032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL347719(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pasteur Msd filed Critical Aventis Pasteur Msd
Publication of PL347719A1 publication Critical patent/PL347719A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL99347719A 1998-11-26 1999-11-25 Multivalent t.d. polio vaccine against at least diphtheria, poliomyelitis and tetanus PL347719A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98122373A EP1004314A1 (de) 1998-11-26 1998-11-26 T.d.Polio Impstoff für einer primovakzinierter oder empfindlicher Population

Publications (1)

Publication Number Publication Date
PL347719A1 true PL347719A1 (en) 2002-04-22

Family

ID=8233032

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99347719A PL347719A1 (en) 1998-11-26 1999-11-25 Multivalent t.d. polio vaccine against at least diphtheria, poliomyelitis and tetanus

Country Status (14)

Country Link
EP (2) EP1004314A1 (de)
JP (1) JP2003525858A (de)
AT (1) ATE281176T1 (de)
AU (1) AU759221B2 (de)
CA (1) CA2352617A1 (de)
CZ (1) CZ20011860A3 (de)
DE (1) DE69921682T2 (de)
DK (1) DK1131094T3 (de)
ES (1) ES2228175T3 (de)
NZ (1) NZ511933A (de)
PL (1) PL347719A1 (de)
PT (1) PT1131094E (de)
WO (1) WO2000030678A1 (de)
ZA (1) ZA200103634B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
WO2008028957A2 (en) * 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Vaccine
CN111032078A (zh) 2017-07-18 2020-04-17 血清研究所印度私人有限公司 具有改善的稳定性、增强的免疫原性和降低的反应原性的免疫原性组合物及其制备方法
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199802783T2 (xx) * 1996-07-02 1999-03-22 Connaught Laboratories Limited �ok de�erli DTP polyo a��lar.
GB9623233D0 (en) * 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
DE69735191T2 (de) * 1997-09-15 2006-10-05 Sanofi Pasteur Msd Verfahren zur Herstellung multivalenter Impfstoffe
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition

Also Published As

Publication number Publication date
PT1131094E (pt) 2005-02-28
DE69921682T2 (de) 2005-11-03
ZA200103634B (en) 2002-05-06
AU1390100A (en) 2000-06-13
EP1131094B1 (de) 2004-11-03
CA2352617A1 (en) 2000-06-02
ES2228175T3 (es) 2005-04-01
EP1131094A1 (de) 2001-09-12
EP1004314A1 (de) 2000-05-31
DE69921682D1 (de) 2004-12-09
JP2003525858A (ja) 2003-09-02
ATE281176T1 (de) 2004-11-15
AU759221B2 (en) 2003-04-10
CZ20011860A3 (cs) 2002-01-16
NZ511933A (en) 2002-09-27
DK1131094T3 (da) 2005-02-14
WO2000030678A1 (fr) 2000-06-02

Similar Documents

Publication Publication Date Title
EA200501070A1 (ru) Поливалентная вакцинная композиция
NZ513202A (en) Antigen composition comprising Bordetella bronchiseptica, formalin and glutaraldehyde
DK0654086T3 (da) Vacciner mod Aujeszky's sygdom og andre dyresygdomme indeholdende mutanter af pseudo-rabies-virus
BR0114786A (pt) Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição
DK0773785T3 (da) Behandling af cancer ced hjælp af HSV-mutant
HK1005541A1 (en) Treatment of helicobacter associated gastroduodenal disease
PL347719A1 (en) Multivalent t.d. polio vaccine against at least diphtheria, poliomyelitis and tetanus
DK0939648T3 (da) Rotavirusvaccineformuleringer
MX9603182A (es) Vacuna de hepatitis b.
DK0589949T3 (da) Hidtil ukendte peptider, fremgangsmåder til fremstilling heraf og anvendelse af disse
NL300336I2 (nl) Vaccin tegen de bof dat een jeryl-lynn virusstam bevat
MA22938A1 (fr) Procede d'obtention d'un vaccin antirabique avirulent.
EP0297051A3 (de) Photopolymerisierbare Zusammensetzung
DK0679378T3 (da) Apparatur til forhindring af snorken
DE69609739D1 (de) Pertussistoxin enthaltender Influenzaimpfstoff
AU2001239231A1 (en) Thermostat valve for radiators
DE69708779D1 (de) Aufhänge- und Klemmsystem
DK0485463T3 (da) Svækket hundeparvovirus (CPV), vaccine omfattende CPV og fremgangsmåde til forebyggelse af CPV-infektion i hunde
DK1149901T3 (da) Mutanter af pestivirus og vacciner indeholdende disse
ITMI911107U1 (it) Supporto per targhetta consentente inserzione, distacco ed estrazione della medesima in modo semplice e spontaneo
NO983580L (no) 5<alfa>-reduktaseinhibitorpreparat for oral administrering, fremgangsmÕte for fremstilling derav og anvendelse derav
GB8919622D0 (en) A method of preparing pyridazinone derivatives
ATE203787T1 (de) Elastische schienenklammern
NZ316110A (en) vaccine containing an antigen from H. Influenzae and an antigen from influenza virus

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)